- Home
- EAD vs IMAB Comparison
EAD vs IMAB Comparison
Compare EAD & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAD
- IMAB
- Stock Information
- Founded
- EAD 2003
- IMAB 2014
- Country
- EAD United States
- IMAB United States
- Employees
- EAD N/A
- IMAB N/A
- Industry
- EAD Finance/Investors Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EAD Finance
- IMAB Health Care
- Exchange
- EAD Nasdaq
- IMAB Nasdaq
- Market Cap
- EAD 419.0M
- IMAB 384.6M
- IPO Year
- EAD N/A
- IMAB 2020
- Fundamental
- Price
- EAD $7.10
- IMAB $3.96
- Analyst Decision
- EAD
- IMAB Strong Buy
- Analyst Count
- EAD 0
- IMAB 5
- Target Price
- EAD N/A
- IMAB $6.80
- AVG Volume (30 Days)
- EAD 178.9K
- IMAB 2.2M
- Earning Date
- EAD 01-01-0001
- IMAB 11-02-2025
- Dividend Yield
- EAD 8.91%
- IMAB N/A
- EPS Growth
- EAD N/A
- IMAB N/A
- EPS
- EAD N/A
- IMAB N/A
- Revenue
- EAD N/A
- IMAB N/A
- Revenue This Year
- EAD N/A
- IMAB N/A
- Revenue Next Year
- EAD N/A
- IMAB N/A
- P/E Ratio
- EAD N/A
- IMAB N/A
- Revenue Growth
- EAD N/A
- IMAB N/A
- 52 Week Low
- EAD $5.69
- IMAB $0.60
- 52 Week High
- EAD $6.81
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- EAD 52.23
- IMAB 48.18
- Support Level
- EAD $7.10
- IMAB $3.20
- Resistance Level
- EAD $7.15
- IMAB $4.64
- Average True Range (ATR)
- EAD 0.03
- IMAB 0.44
- MACD
- EAD -0.00
- IMAB -0.15
- Stochastic Oscillator
- EAD 50.00
- IMAB 33.93
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).